About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, December 15th, 2015

The QualityStocks
Daily Stock List


TapImmune, Inc. (TPIV)

PennyStocks24, StockOnion, SecretStockPromo, Penny Pick Finders, PennyStockProphet, Buzz Stocks, and Planet Penny Stocks reported earlier on TapImmune, Inc. (TPIV), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed TapImmune, Inc. is a vaccine technologies company that specializes in the development of inventive gene based immunotherapeutics and vaccines in the areas of oncology and infectious disease. It is developing TAP-based prophylactic vaccines commercially suitable for the prevention of infectious diseases and as Biodefense agents. Jacksonville, Florida-based TapImmune is developing cancer vaccines that combine the use of novel antigens together with its TAP expression technology. TapImmune’s technology has all-inclusive applications in developing therapeutic and preventative vaccines.

TapImmune has developed a unique, cost effective, immunotherapeutic vaccine expression and delivery system. The novel platform is called TapImmune's PolyStart™ technology. The PolyStart and PAA (Peptide Antigen Array) technologies are straight forwardly and easily managed as a quick, versatile, plugin-and-play system. This means they can be configured to produce peptides for any desired pathogen.

TapImmune's PolyStart™ technology has been strategically designed to directly enhance the immune system's ability to stimulate either or both cytotoxic killer and helper T-cell reactive proprietary peptides, known and expected to be associated with one, or any cancer, infectious disease, or bio-threat. The current focus of its PolyStart technology is on its cancer program (e.g., Her2/neu and folate receptor alpha antigens).

The gene based TAP technology, as a vaccine component, has the potential to improve the efficacy of prophylactic and immunotherapeutic vaccines substantially. This is because it addresses a fundamental mechanism for T cell recognition and response. TAP expression also has the unique ability to enhance the effector function of mature killer T cells. This enhancement of effector function is potentially complementary to any/all vaccine approaches designed to enhance cellular responses.

TapImmune’s lead product candidates include peptide and nucleic acid-based vaccine technologies. The design of these technologies is to restore and/or augment antigen presentation and subsequent recognition and killing of cancer cells by the immune system.   

The Company’s vaccine is to be studied in a $13.3 Million U.S. Department of Defense grant to Mayo Clinic for a Phase II Clinical Trial in Triple Negative Breast Cancer. The trial will use the Folate Receptor Alpha Vaccine licensed to TapImmune for commercialization. TapImmune has the commercial rights for this vaccine, which has the potential to treat ovarian, breast, endometrial and non-small cell lung cancer.

Last week, TapImmune announced that it received Orphan Drug Designation from the U.S. Food & Drug Administration's Office of Orphan Products Development (OOPD) for its cancer vaccine TPIV 200 in the treatment of ovarian cancer. The TPIV 200 ovarian cancer clinical program will now receive benefits. These include tax credits on clinical research and 7-year market exclusivity upon receiving marketing approval.

TapImmune, Inc. (TPIV), closed Tuesday's trading session at $0.655, down 2.96%, on 657,123 volume with 230 trades. The average volume for the last 60 days is 843,604 and the stock's 52-week low/high is $0.121/$1.71.

Soligenix, Inc. (SNGX)

OTC Markets Group, PennyStocks24, Pennybuster, Streetwise Reports, and InvestorPlace reported on Soligenix, Inc. (SNGX), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Soligenix, Inc. is a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology, and biodefense. The Company’s proprietary vaccine thermostabilization technology is ThermoVax™.  Soligenix’s areas of emphasis include a therapeutics segment devoted to the development of products for orphan diseases and areas of unmet medical need. This includes cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn's disease, acute radiation enteritis, and Graft-versus-Host disease (GVHD). Soligenix’
Soligenix’s second area of emphasis is a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis. It is developing proprietary formulations of oral BDP (beclomethasone 17,21-dipropionate) for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation. This includes pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201).

Soligenix is also advancing its novel innate defense regulator (IDR) technology SGX942 for the treatment of oral mucositis and SGX301, its novel first-in-class photodynamic technology using synthetic hypericin with safe visible light, for the treatment of cutaneous T-cell lymphoma. The Company’s biodefense products undergoing development include a recombinant subunit vaccine called RiVax™. The design of it is to protect against the lethal effects of exposure to ricin toxin. RiVax™ has been granted orphan drug designation by the Food and Drug Administration (FDA) for the prevention of ricin intoxication.

It is also developing VeloThrax™, a vaccine against anthrax exposure, and OrbeShield™ for the treatment of gastrointestinal acute radiation syndrome (GI ARS) under a BARDA (Biomedical Advanced Research and Development Authority) contract award. Additionally, it has an exclusive global collaboration with Intrexon Corp. (XON). The focus of it is on the joint development of a treatment for Melioidosis, a high priority biothreat and an area of unmet medical need.

Yesterday, Soligenix announced that patient enrollment has been opened for its Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating SGX301 (synthetic hypericin), as a treatment for cutaneous T-cell lymphoma (CTCL).  SGX301 has earlier been granted orphan drug and fast track designations from the FDA for the first-line treatment of CTCL, a rare disease and a class of non-Hodgkin's lymphoma.

Soligenix, Inc. (SNGX), closed Tuesday's trading session at $0.57, up 3.64%, on 1,124,484 volume with 87 trades. The average volume for the last 60 days is 188,350 and the stock's 52-week low/high is $0.4401/$2.95.

BIO-key International, Inc. (BKYI)

Zacks and SmallCapVoice reported earlier on BIO-key International, Inc. (BKYI), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

BIO-key International, Inc. is a leader in fingerprint biometric identification technologies, secure cloud- and device-based mobile credentialing, and identity verification solutions. It develops and delivers advanced identification solutions to commercial and government enterprises, integrators, and custom application developers. BIO-key International lists on the OTCQB and the Company has its headquarters in Wall, New Jersey.

Its technology is offered directly or by market leading partners globally. BIO-key’s solutions are used in local embedded original equipment manufacturer (OEM) products and some of the world's largest identification deployments to improve security, guarantee identity, and help reduce identity theft. BIO-key International helps customers reduce risk and protect the value of their services and assets, while minimizing the continuing costs for Access Control and Identity Management.

Its biometric finger identification technology is award winning, high performance, scalable, cost-effective, and easy-to-deploy. It accurately identifies and authenticates users of wireless and enterprise applications. BIO-key’s products include SideSwipe® Mini Fingerprint Reader, Web-key®, VST-Vector Segment Technology™, ID Director for Allscripts HER, ID Director for EpicCare, ID Director for CA SiteMinder, ID Director for IBM ISAM for Web, BIO-key BSP for IBM ESSO, BIO-key BSP for Oracle Access Manager, and ID Director for Windows.

The Company’s fingerprint authentication solutions support its Meaningful Use roadmaps and meet compliance guidelines from the U.S. Drug Enforcement Agency (DEA) and respective State Boards of Pharmacy. Fingerprint authentication has become the preferred authentication option in Healthcare for meeting Meaningful Use, EPCS, I-STOP, CPOE and other requirements.

Last month, BIO-key International reported that it executed a strategic technology license agreement with affiliates of China Goldjoy Group Limited (CGG), and purchase agreements in association with a $10.5 million private placement of convertible preferred equity with a wholly-owned indirect subsidiary of CGG and a third investor, and an additional $550,000 investment in its Series A-1 Convertible Preferred Shares.

In combination with the private placement transactions, BIO-key Hong Kong Ltd. secured a commercial license to a portfolio of mobile and online payment and security software technologies from certain subsidiaries of CGG for a one-time payment of $12 million. BIO-key's strategy is to take advantage of its biometric matching solutions and WEB-key secure biometric cloud transport offerings along with the mobile and online payment technologies licensed from such subsidiaries of CGG.

BIO-key International, Inc. (BKYI), closed Tuesday's trading session at $0.1875, up 1.90%, on 155,400 volume with 21 trades. The average volume for the last 60 days is 85,331 and the stock's 52-week low/high is $0.10/$0.50.

SolarWindow Technologies, Inc. (WNDW)

SmallCapVoice reported earlier on SolarWindow Technologies, Inc. (WNDW), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Columbia, Maryland-based SolarWindow Technologies, Inc. is a developer of next generation electricity-generating SolarWindow™ coatings. Its mission has been to create SolarWindow™ products that generate considerable amounts of clean electricity, financially reward its customers, and benefit the environment. SolarWindow™ is the subject of a patent pending technology. The Company was formerly known as New Energy Technologies, Inc. It changed its name to SolarWindow Technologies, Inc. in March of 2015.

SolarWindow™ coatings generate electricity on see-through glass and flexible plastics with colored tints popular to skyscraper glass. SolarWindow™ uses organic materials that are dissolved into liquid, best for low-cost high-output manufacturing. SolarWindow™ systems can be installed on the readily-available sizeable window glass surfaces on tall towers and skyscrapers. SolarWindow™ can be applied to the sides of tall towers, producing electricity using natural, shaded, and artificial light.

Basically, SolarWindow Technologies’ SolarWindow™ products are undergoing development to be installed on all four sides of a skyscraper. This turns the entire building into a power generator. Commercial buildings account for 35 percent of all electricity consumed. Therefore, SolarWindow Technologies believes this market opportunity is especially important.

SolarWindow Technologies announced this past April that engineers and research scientists at the University of North Carolina Charlotte Energy Production and Infrastructure Center (UNCC-EPIC) independently reviewed and validated the Company’s SolarWindow™ proprietary Power Production and Financial Model. This Model calculates a financial payback of under one year for SolarWindow’s transparent electricity-generating SolarWindow™ technology. To produce the equivalent amount of power with traditional solar systems would require a minimum of 5-11 years for payback and a minimum 10-12 acres of valuable urban land.

SolarWindow Technologies’ latest products will be engineered as transparent, tinted, flexible veneers that installers can apply directly over top of existing windows on tall towers and skyscrapers. This expanded product line extends the Company’s market reach beyond new and replacement installations, to include windows now installed on the estimated five million commercial buildings constructed in the U.S. alone.

SolarWindow Technologies’ said last week that its independently validated modeling shows that when SolarWindow™ is applied to all sides of a 50-story building, the results include 50 times greater energy than conventional rooftop solar panels; 15 times the environmental benefits over traditional rooftop solar energy collectors; electricity generated from natural, shaded, reflected, and indoor light and the above-mentioned one-year financial payback.

SolarWindow Technologies, Inc. (WNDW), closed Tuesday's trading session at $3.78, up 7.39%, on 350,822 volume with 777 trades. The average volume for the last 60 days is 69,590 and the stock's 52-week low/high is $1.22/$3.99.

Direct Insite Corp. (DIRI)

RedChip and Zacks reported earlier on Direct Insite Corp. (DIRI), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Direct Insite Corp. provides a strong platform for unified working capital management, which facilitates greater than $160 billion worth of transactions each year between greater than 375,000 companies globally. The Company is the provider of the PAYBOX® integrated receivables platform. PAYBOX® mainly sells through banks to corporate users of their treasury management and lockbox services. Direct Insite has its headquarters in Fort Lauderdale, Florida.

Services that the Company provides include business case support, business process and technology review, business process re-engineering, workflow management, automation best practices, and deployment strategies. Furthermore, Direct Insite provides project management support, complete staff training, administrator training, supplier on-boarding services, and expert support.

Its PAYBOX® is an integrated receivables solution. It combines electronic invoicing, online approvals and adjustments, electronic payments, and integration with any legacy accounting, ERP or lockbox system. PAYBOX® is used by banks and corporations to reduce Days Sales Outstanding, lower costs, and improve straight-through accounts receivable (AR) posting.

The Company’s AR Solutions include PAYBOX® for Corporates and PAYBOX® for Banks. Direct Insite provides a range of consulting, implementation, support and educational services to help ensure the success of an organization’s accounts payable (AP), accounts receivable (AR) and payments automation projects. In addition, Direct Insite offers best-in-class supplier on-boarding services proven to increase E-invoicing adoption.

Recently, Direct Insite announced that it further enhanced its PAYBOX® unified working capital management platform. Additional functionality includes the digital capture of payment and remittance information matched with the PAYBOX® CORE invoice distribution product, creating a complete integrated receivables offering, benefiting banks and their corporate customers.

Direct Insite Chairman and Chief Executive Officer, Mr. Matthew E. Oakes, said, "PAYBOX® Integrated Receivables transforms an invoicing product into a true integrated receivables service. You can't have an integrated receivables product without the invoice, and this is the only platform on the market where the invoice stays with the transaction throughout the entire process in a secure SAAS environment."

Direct Insite Corp. (DIRI), closed Tuesday's trading session at $0.6035, up 11.76%, on 28,534 volume with 18 trades. The average volume for the last 60 days is 2,568 and the stock's 52-week low/high is $0.51/$1.18.


The QualityStocks
Company Corner


Avant Diagnostics, Inc. (AVDX)

The QualityStocks Daily Newsletter would like to spotlight Avant Diagnostics, Inc. (AVDX). Today, Avant Diagnostics, Inc. closed trading at $0.35, up 16.67%, on 3,221 volume with 7 trades. The stock’s average daily volume over the past 60 days is 1,990, and its 52-week low/high is $0.2002/$1.95.

Avant Diagnostics, Inc. unveiled its new website on December 12, 2015. The site, avantdiagnostics.com, incorporates numerous features to make browsing a more streamlined and informative experience for the Company's current and potential customers and investors. Major features of the new site include imagery, look, branding and content. Gregg Linn, President and Chief Executive Officer of Avant, said, "A significant part of Avant's mission is presenting those interested in the company with the information they want in the quickest and most organized way. We believe our new website advances this goal by presenting our range of services and activities in an attractive and easy-to-access format. As our official online portal, it accurately reflects the variety and excitement of what we have to offer to those with whom we do business."

Avant Diagnostics, Inc. (AVDX) is a medical diagnostic technology company that specializes in large panel biomarker screening. The company's first test, OvaDx®, is a sophisticated microarray-based test designed to detect pre-symptomatic ovarian cancer by measuring the activation of the immune system in blood samples in response to early stage ovarian tumor cell development.

In clinical development, OvaDx has indicated high sensitivity and specificity for all types and stages of ovarian cancer, including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous and ovarian adenocarcinoma. Upon FDA approval, Avant plans to offer its diagnostic product as an elective test for women seeking greater wellness, as well as those in the elevated risk category for ovarian cancer.

OvaDx is also expected to be used by doctors to advance the forefront of ovarian cancer treatment, promoting the utilization of improved surgical options and more effective chemotherapies by serving as a supplement to existing tests, such as CA-125, OVA1® and transvaginal ultrasound. In this way, Avant's innovative product will promote earlier diagnoses and, as a result, improved survival rates for patients with ovarian cancer.

As it continues to seek FDA approval for its groundbreaking diagnostic technology, Avant is poised to promote considerable growth in the ovarian cancer market, addressing what is currently the most deadly cancer of the female reproductive system. The company will lean on the industry experience of its management team in order to continue positioning itself for long-term success in the medical diagnostic market. Disclaimer

Avant Diagnostics, Inc. Company Blog

Avant Diagnostics, Inc. News:

Avant Diagnostics, Inc. Announces Launch of New Corporate Website

Avant Diagnostics Inc. Receives FDA IRB Approval for OvaDx(R) Ovarian Cancer Validation Test Specimens

Avant Diagnostics Inc. Engages Goal Capital Inc. to Provide Investor Relations Services

Hemp, Inc. (HEMP)

The QualityStocks Daily Newsletter would like to spotlight Hemp, Inc. (HEMP). Today, Hemp, Inc. closed trading at $0.051, off by 5.56%, on 2,217,219 volume with 154 trades. The stock’s average daily volume over the past 60 days is 3,536,405, and its 52-week low/high is $0.039/$1.00.

Hemp, Inc. executives today report how industrial hemp has been sweeping across the nation through the news. Industrial hemp, the plant which has been used for thousands of years in all major areas of commerce until the 1930s, continues to surface on the media circuit from state to state. The versatility of the hemp plant in modern American use has been distorted due to vague distinctions from its cousin, marijuana; however, Hemp, Inc. executives feel their shareholders, potential shareholders and all others should be informed of "industry material events" to keep them informed of hemp legislation and rapidly changing laws in the industry.

Hemp, Inc. (HEMP) is engaged in the research and development of all things made of industrial hemp. From fabric, paper, cosmetics, food and jewelry to pulp, fuel, paints and more, the application of hemp represents a myriad of possibilities. The company strategizes to recognize the profits that could be made in making the world a better place through the industrial commercialization of this resource.

Hemp, Inc. subsidiaries include Industrial Hemp Manufacturing, LLC, which will soon be offering DrillWall™ for maintaining the seals on drilling for water, oil, gas and any other liquid or gas; and The Industrial Hemp and Medical Marijuana Consulting Company, Inc., which pulls pertinent market information from a vast network of professionals, specialists and experts from various niches of the hemp industry.

Las Vegas-based Hemp, Inc. conducts its operations through its 70,000-square-foot processing plant and decortication line of equipment, which is useful manufacturing more than 50,000 commercial products. The company's current line of offerings include hemp-infused body candles, shampoo and conditioner, smoothies, jewelry, healing oils, twine, lip balm and skin moisturizers.

Hemp products are used all over America every day and are sold in the largest and most respected stores. Not to be confused with marijuana, hemp does not contain psychoactive compounds and is legal in the United States and most of the world. Hemp, Inc.'s mission is to educate the public on this important differentiation while working to expand corporate infrastructure and invest in profitable, legal and diversified ventures poised to bring reward and value to shareholders. Disclaimer

Hemp, Inc. Company Blog

Hemp, Inc. News:

Industrial Hemp Is Sweeping America in the News

Hemp, Inc. CEO Receives the 1st Annual Jack Herer Cannabis Hemp Award

Two Days Left to Buy Hemp Jeans by Hemp Blue

Legacy Ventures International, Inc. (LGYV)

The QualityStocks Daily Newsletter would like to spotlight Legacy Ventures International, Inc. (LGYV). Today, Legacy Ventures International, Inc. closed trading at $1.51, off by 24.88%, on 398,155 volume with 389 trades. The stock’s average daily volume over the past 60 days is 21,207, and its 52-week low/high is $0.01/$2.50.

Legacy Ventures International, Inc. recently announced that it is now compliant with Blue Sky Laws in 46 states representing 92.7% of the US population. In addition, the company has entered into a distribution agreement with Sysco in Toronto, a leader in the food services industry. Boxed Water provides an alternative sustainable package for water consumption as it is packaged in a 100% recyclable carton and not a plastic bottle. In shipping alone, Boxed Water significantly lowers their carbon footprint; 1 truckload of Boxed Water cartons is equivalent to 26 truckloads of plastic bottles. Boxed Water supports world water relief, reforestation, and environmental protection projects. With the recent climate agreement reached in Paris, Legacy Ventures is in a position of change.

Legacy Ventures International, Inc. (LGYV) is an investment company seeking out high-potential businesses with big ideas that can be scaled in order to promote hyper growth. The company fuels innovation and passion by providing the capital, oversight and connections that young businesses need to reach their full potential.

Legacy is led by a highly-qualified executive team with decades of relevant industry experience. Evan Clifford, the company's chief executive officer, has spent more than 15 years building and maintaining relationships with some of North America's most influential executives. Over the past decade, he has served as a lead advisor to a collection of companies and individuals striving for personal and professional success. Likewise, Rehan Saeed, Legacy's chief financial officer, has over a decade of experience in the banking industry during which he built and managed a real estate portfolio valued at $110 million.

The company's current brand portfolio is headlined by newly-acquired RM Fresh Brands, a servicer of food and beverage retailers and distributors around the globe. RM Fresh Brands takes a unique approach to brand partnerships by maintaining a clear focus on sustainable, category-changing consumables. This strategy has helped it build an extensive portfolio of highly-desirable brands – including Boxed Water, Aloe Gloe, Uncle Si's Iced Tea and Chef 5-Minute Meals.

Following the successful acquisition of RM Fresh Brands, Legacy is in a strong strategic position to move forward with its efforts to promote sustainable growth. The company will lean on the considerable experience of its management team as it looks to build on its recent progress while promoting maximized shareholder value. Disclaimer

Legacy Ventures International, Inc. Company Blog

Legacy Ventures International, Inc. News:

Legacy Ventures International Due Diligence Report: Being Green is in; Boxed Water a Step Closer to Reducing the Carbon Footprint

Legacy Ventures Subsidiary RM Fresh Brands Completes Agreement to Supply Products to Sysco for Distribution

Legacy Ventures Now Blue Sky Compliant

Alternet Systems, Inc. (ALYI)

The QualityStocks Daily Newsletter would like to spotlight Alternet Systems, Inc. (ALYI). Today, Alternet Systems, Inc. closed trading at $0.0148, up 48.00%, on 100 volume with 1 trade. The stock’s average daily volume over the past 60 days is 205,365, and its 52-week low/high is $0.0055/$0.045.

Alternet Systems, Inc. (ALYI) invests in and partners with companies that are creating the future of money in the high growth, emerging technology fields of digital commerce, multichannel payments, and predictive analytics.

Vision: Be the leading digital commerce, multichannel payments, predictive analytics solutions provider into global markets

Mission: To provide innovative solutions that facilitates and expedites commerce, enriching our partners and their customers' experience, and improving efficiency. Recognizing that the world is becoming increasingly dependent on technological conveniences, Alternet Systems aims to provide its customers with the tools to prepare themselves for a new era of digital commerce and payments, financial services and consumer information, and, most importantly, a new era of how to live.

Since 2010, Alternet has maintained a progressive focus on the high-growth, mobile value-added service industries of mobile financial services and mobile security. In 2014, the company expanded its scope of expertise to include in its investment verticals the exciting digital commerce space, transforming the legacy electronic payments infrastructure and developing advanced predictive data analytics applications for the mass consumer, telecommunications and financial industry.

With strategic investments in these three key, high-growth markets, Alternet is accelerating the future of money and its role in the global demand for these services. The company is guided by a team of executives specializing in entrepreneurial endeavors, innovation, corporate strategy, financial and executive management of multi-national organizations, and a vast network of industry resources.

As Alternet embarks on this new path, the company will be led by a management team and board of directors with over a century's worth of combined experience in the fields of investing, technology, and financing, and the consensus knowledge of where to invest and when in start-up and early-stage companies. Disclaimer

Alternet Systems, Inc. Company Blog

Alternet Systems, Inc. News:

Alternet Systems (ALYI) CEO Featured in Exclusive QualityStocks Interview

Alternet Payment Solutions Offers Disruptive Omni-Channel Payment Processing Technology in the U.S.

Alternet Systems Appoints Fabio Alvino as CEO of Alternet Payment Solutions

Moxian, Inc. (MOXC)

The QualityStocks Daily Newsletter would like to spotlight Moxian, Inc. (MOXC). Today, Moxian, Inc. closed trading at $5.04, even for the day, on 100 volume with 1 trade. The stock’s average daily volume over the past 60 days is 739, and its 52-week low/high is $5.00/$6.50.

Moxian, Inc. (MOXC) engages in the business of providing social marketing and promotion platforms designed to help merchants accelerate and advertise their business growth through social media. These products and services enable merchants to run targeted advertising campaigns and promotions, and aim to enhance the interaction between users and merchant clients by using consumer behavior data compiled from the Moxian database of user activities. The company has two primary core products: Moxian+ User App and Moxian+ Business App.

Developed in Shenzhen, China, Moxian integrates social media, entertainment and business intelligence. The Multi-Channel Social Commerce Platform, which includes a variety of tools such as Moxian's proprietary Social Customer Relationship Management (SCRM) system, generates knowledgeable data for merchants. This way, consumers and businesses are able to connect and interact with one another to achieve the concept of "online lifestyle, offline fun."

Moxian+ User App serves as an App driven for consumer users to use the platform, consisting of our proprietary virtual currency (MO-Coin and MO-Points), social networking, redemption centre and game centre. Users can earn MO-Coins by playing games, and then use those coins to redeem prizes sponsored by Moxian and client merchants. This model not only drives registered consumers to Moxian and merchant, but also provides merchants the opportunity to advertise, run marketing campaigns, and learn about their customers through the Platform.

Moxian+ Business App is an independent App with built in Social Customer Relationship Management tool built for merchants. Merchants are able to set up a store on the Moxian platform through this business App, push promotions via a variety of methods offered on the platform and look at generated report customized to their own shop.

Moxian's management team has more than 100 years of combined experience in a variety of pertinent endeavors, including management of private and public enterprise, multi-national organizations, quality, engineering and procurement, finance, marketing, communication and more. Together, Moxian's management team is effecting the company's aim to create and lead a personalized social network platform that best fits users and businesses. Disclaimer

Moxian, Inc. Company Blog

Moxian, Inc. News:

MissionIR Exclusive Audio Interview With Moxian, Inc. (MOXC) Creative & Marketing VP Edmund Ooi

Moxian, Inc. (MOXC) Announces Engagement of DreamTeamNetwork Corporate Communications Service Suite

Moxian Announces China New Media Integrated Development Conference Sponsorship Agreement Has Changed


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters







Wall Street Resources

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251